Synta
Pharmaceuticals announced earlier today the recruitment of Steven Bernitz to
the position of Senior Vice President, Corporate Development. Bernitz brings
with him over 20 years of experience in corporate strategy, business leadership
and transactional experience in life sciences.
Prior
to Synta, Bernitz was a General Partner and Head of the BioPharma Practice at
Extera Partners, a business development advisory firm. While at Extera, Bernitz
directed a number of business development and strategy initiatives for
development stage companies and their investors in areas such as autoimmune,
oncology, and orphan diseases.
Before
joining Extera in 2010, Bernitz held the role of Chief Business Officer at
Concert Pharmaceuticals where he oversaw Concert’s $1 billion deal with
GlaxoSmithKline. Prior to Concert he sat as Senior Vice President, Business and
Product Development at Coley Pharmaceutical Group, where he led a plethora of
transactions including Coley’s $600 million oncology deal with Pfizer. In
addition, Bernitz’s experience includes acting as CEO of Histogenics and
Organogenesis, both cell therapy companies, and before that he was with Merck
Vaccines and McKinsey & Co.
“Steve
has tremendous deal experience, as is clear from his track record, which will
be valuable in realizing the potential of both our ganetespib and HDC
programs,” stated Safi Bahcall, President and CEO, Synta. “His wealth of
diverse business experiences and insights make him an excellent addition to our
executive team, as we manage a growing pipeline and an increasing number of
important strategic and operational choices.”
“Synta
has the potential to make a tremendous difference in the lives of cancer
patients,” commented Bernitz. “Both ganetespib and the HDC platform represent
innovative new treatment approaches that can transform standard of care. I am
excited to join the team and help achieve these ambitious goals.”
Bernitz
holds an MBA from the J.L. Kellogg Graduate School of Management at
Northwestern University, where he was an Austin Scholar. His B.S. summa cum
laude is from Tufts University, where he was elected to Phi Beta Kappa.
For
more information, please visit www.syntapharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
